Prostate-specific antigen testing in Ontario: Reasons for testing patients without diagnosed prostate cancer

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 1, 1999, Pages 70-75

  Bunting, Peter S ^a,e   Goel, Vivek ^b,c   Williams, J Ivan ^b,c   Iscoe, Neill A ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANADA; CANCER SCREENING; DATA BASE; DRUG THERAPY; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICAL RECORD; MEDICAL SPECIALIST; PHYSICIAN; PROSTATE CANCER; QUESTIONNAIRE; SYMPTOM; UROLOGY;

EID: 0033547799     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. 1. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
2. 2. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation and outcomes. The Prostate Patient Outcome Research Team. JAMA 1993;269:2633-55.
3. 3. Voges GE, McNeal JE, Redwine EA, Freiha FS, Stamey TS. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 1992;69:520-6.
4. 4. Bowersox J. American Cancer Society adopts new prostate cancer screening guidelines. J Natl Cancer Inst 1992;84:1856-7.
5. 5. Mettlin C, Jones GW, Averette H, Gusberg SB Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer related checkup: prostate and endometrial cancer. Cancer J Clinicians 1993;43:42-6.
6. 6. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med 1995;333:1401-5.
7. 7. Early detection of prostate cancer. Practice guideline of the Canadian Urological Association. Edmonton: Canadian Urological Association; 1996.
8. 8. Early detection of prostate cancer. Practice guidelines of the American Urological Association. Baltimore: American Urological Association; 1995.
9. 9. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-23.
10. 10. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Urology 1995;46:445-61.
11. 11. Prostate cancer screening. Sydney, Australia: Australian Health Technology Advisory Committee; 1996.
12. 12. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997;1(2).
13. 13. US Preventive Services Task Force. Screening for prostate cancer: a commentary on the Canadian Task Force on the Periodic Health Examination 1991 update on the secondary prevention of prostate cancer. Am J Prev Med 1994;10:187-93.
14. 14. Feightner JW. Screening for prostate cancer. In: Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care. Ottawa: Ministry of Supply and Services Canada, 1994. p. 811-23.
15. 15. Bunting PS, Miyazaki JE, Goel V. Laboratory survey of prostate-specific antigen testing in Ontario: the provincial workload count. Clin Biochem 1998; 31:47-9.
16. 16. Mercer SL, Goel V, Levy IG, Ashbury FD, Iverson DC, Iscoe NA. Prostate cancer screening in the midst of controversy. Canadian men's knowledge, beliefs, utilization and future intentions. Can J Public Health 1997;88:327-32.
17. 17. The PSA test in the early detection of prostate cancer. Final report. Saskatoon: Health Services Utilization and Research Commission, Government of Saskatchewan; 1995.
18. 18. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects, and costs. Montreal: Conseil d'évaluation des technologies de la santé du Québec; 1995.
19. 19. Sheatsley PB. Questionnaire construction and item writing. In: Handbook of survey research. New York: Academic Press; 1983. p. 195-230.
20. 20. Woodward CA, Chambers LW. Guide to questionnaire construction and question writing. Ottawa: Canadian Public Health Association; 1991.
21. 21. Woodward CA, Chambers LW, Smith KD. Guide to improved data collection in health and health care surveys. Ottawa: Canadian Public Health Association; 1991.
22. 22. Streiner DL, Norman GR. Methods of administration. In: Health measurement scales: a practical guide to their development and use. 2nd ed. New York: Oxford University Press; 1995. p 188.
23. 23. Dillman DA. Mail and telephone surveys: the total design method. Toronto: John Wiley and Sons; 1978.
24. 24. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al, and the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57.
25. 25. Hoffman RM, Papeniuss MR, Buller DB, Moon TE. Attitudes and practices of primary care physicians for prostate cancer screening. Am J Prev Med 1996;12:277-81.
26. 26. Plawker MW, Fleisher JM, Nitti VW, Macchia RJ. Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer. J Urol 1996;155:601-4.
27. 27. Hansen MV, Gronberg A. Attitudes of European urologists to early prostatic carcinoma: II. Attitude to therapy and to screening examinations. Eur Urol 1995;28:196-201.
28. 28. Plawker MW, Fleisher JM, Vapnek EM, Macchia RJ. Current trends in prostate cancer diagnosis and staging among United States urologists. J Urol 1997;158:1853-8.